Keywords: Patent cliffs, R&D, Development costs, USA, FDA, Tufts

Facing patent cliffs, drug developers are aggressively changing the way they do R&D, says Tufts

Article | 6 January 2011

With dozens of prescription drugs due to lose their patent protection over the next several years, and few likely blockbusters ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in